9-β-D-Arabinofuranosylguanine

[1]  Yurong Lai,et al.  Mitochondrial Expression of the Human Equilibrative Nucleoside Transporter 1 (hENT1) Results in Enhanced Mitochondrial Toxicity of Antiviral Drugs* , 2004, Journal of Biological Chemistry.

[2]  C. M. Stellrecht,et al.  Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. , 2003, Blood.

[3]  B. Zhivotovsky,et al.  Effects of 9-beta-D-arabinofuranosylguanine on mitochondria in CEM T-lymphoblast leukemia cells. , 2003, Biochemical and biophysical research communications.

[4]  B. Mitchell,et al.  Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. , 2002, Cancer research.

[5]  S. Eriksson,et al.  Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-beta-D-arabinofuranosylguanine cytotoxicity. , 2002, Biochemical and biophysical research communications.

[6]  H. Mandel,et al.  Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy , 2001, Nature Genetics.

[7]  H. Mandel,et al.  The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA , 2001, Nature Genetics.

[8]  J. Balzarini,et al.  Dual mechanisms of 9-beta-D-arabinofuranosylguanine resistance in CEM T-lymphoblast leukemia cells. , 2001, Biochemical and biophysical research communications.

[9]  Kenneth A. Johnson,et al.  Insights into the Molecular Mechanism of Mitochondrial Toxicity by AIDS Drugs* , 2001, The Journal of Biological Chemistry.

[10]  J. Mackey,et al.  Nucleoside analogues: mechanisms of drug resistance and reversal strategies , 2001, Leukemia.

[11]  G. Rosner,et al.  Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Walker,et al.  The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Johnson,et al.  In vitro chemo-sensitivity of B-chronic lymphocytic leukaemia to ara-G. , 2000, Leukemia research.

[14]  Pier Paolo Pandolfi,et al.  Mitochondrial Basis for Immune Deficiency: Evidence from Purine Nucleoside Phosphorylase–Deficient Mice , 2000 .

[15]  A. Karlsson,et al.  Differential incorporation of 1‐β‐D‐arabinofuranosylcytosine and 9‐β‐D‐arabinofuranosylguanine into nuclear and mitochondrial DNA , 2000 .

[16]  Xiaodong Wang,et al.  Nucleotide Requirements for the in Vitro Activation of the Apoptosis Protein-activating Factor-1-mediated Caspase Pathway* , 2000, The Journal of Biological Chemistry.

[17]  V. Gandhi,et al.  Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. , 1999, Cancer research.

[18]  J. Kurtzberg,et al.  Complete hematologic and cytogenetic response to 2‐amino‐9‐β‐D‐arabinosyl‐6‐methoxy‐9H‐guanine in a patient with chronic myelogeneous leukemia in T‐cell blastic phase , 1999, Cancer.

[19]  J. Kurtzberg,et al.  Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Smeitink,et al.  Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway , 1998, AIDS.

[21]  J. Goldman,et al.  Busulfan alone as cytoreduction before autografting for chronic myelogenous leukemia. , 1998, Blood.

[22]  P. Hentosh,et al.  2-Chloro-2'-deoxyadenosine, an antileukemic drug, has an early effect on cellular mitochondrial function. , 1997, Molecular pharmacology.

[23]  L. Hertel,et al.  Medicinal chemistry of difluoropurines. , 1995, Seminars in oncology.

[24]  A. J. Chapman,et al.  Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. , 1995, Seminars in oncology.

[25]  J. Wilson,et al.  2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. , 1995, Cancer research.

[26]  A. Karlsson,et al.  Differences in kinetic properties of pure recombinant human and mouse deoxycytidine kinase. , 1995, Biochemical pharmacology.

[27]  M. Dalakas,et al.  Mitochondrial toxicity of antiviral drugs , 1995, Nature Medicine.

[28]  J. Beckmann,et al.  A gene for familial juvenile nephronophthisis (recessive medullary cystic kidney disease) maps to chromosome 2p , 1993, Nature Genetics.

[29]  D. Shibata,et al.  Epstein-Barr virus genotypes in AIDS-associated lymphomas are similar to those in endemic Burkitt's lymphomas. , 1992, Leukemia.

[30]  C. H. Chen,et al.  The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2',3'-dideoxycytidine. , 1992, The Journal of biological chemistry.

[31]  J. Kurtzberg,et al.  PHARMACOLOGIC PURGING OF MALIGNANT T CELLS FROM HUMAN BONE MARROW USING 9‐β‐D‐ARABINOFURANOSYLGUANINE , 1991, Transplantation.

[32]  B. Mitchell,et al.  Differential metabolism of 9-β-D-arabinofuranosylguanine in human leukemic cells , 1989 .

[33]  W. Plunkett,et al.  Interaction of arabinosyl nucleotides in K562 human leukemia cells. , 1989, Biochemical pharmacology.

[34]  W. Plunkett,et al.  Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. , 1988, Cancer research.

[35]  B. Mitchell,et al.  Characterization of arabinosylguanine resistance in a lymphoblastoid cell line. , 1986, Advances in experimental medicine and biology.

[36]  S. K. Wadman,et al.  Mechanisms of deoxyguanosine toxicity for human T and B lymphocytes. , 1986, Advances in experimental medicine and biology.

[37]  A. Fridland,et al.  Metabolism and Selectivity of Arabinonucleoside in Human Lymphoid Cells 1 , 1985, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[38]  A. Fridland,et al.  Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. , 1985, Cancer research.

[39]  P. Daddona,et al.  Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts. , 1985, Cancer research.

[40]  G. Koszalka,et al.  Purine nucleoside synthesis, an efficient method employing nucleoside phosphorylases. , 1981, Biochemistry.

[41]  P. Daddona,et al.  Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[42]  David W. Martin,et al.  Deoxyguanosine toxicity in a mouse T lymphoma: Relationship to purine nucleoside phosphorylase-associated immune dysfunction , 1978, Cell.

[43]  J. Kaye,et al.  Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Ammann,et al.  NUCLEOSIDE-PHOSPHORYLASE DEFICIENCY IN A CHILD WITH SEVERELY DEFECTIVE T-CELL IMMUNITY AND NORMAL B-CELL IMMUNITY , 1975, The Lancet.

[45]  J. Schenkman,et al.  The relationship between the pH-induced spectral change in ferriprotoheme and the substrate-induced spectral change of the hepatic microsomal mixed-function oxidase. , 1968, Molecular pharmacology.

[46]  L. Goodman,et al.  SYNTHESIS OF 9-BETA-D-ARABINOFURANOSYLGUANINE. , 1964, Biochemistry.